Pharmacotherapies for COPD

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Expert Review

Stan Ejiofor¹  Alice M. Turner² 

[1] Russells Hall Hospital, Dudley, West Midlands, UK.;University of Birmingham, QEHB Research Labs, Birmingham, West Midlands, UK.;Heart of England NHS Foundation Trust, Birmingham, West Midlands, UK.;

关键词: chronic obstructive pulmonary disease;    pharmacotherapies;    disease management;   

DOI  :  10.4137/CCRPM.S7211

来源: Sage Journals

【 摘 要 】

This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.

【 授权许可】

CC BY-NC   
© 2013 SAGE Publications.

【 图 表 】

Figure 9.

Figure 8.

Figure 7.

Figure 1b.

Figure 6.

Figure 5.